The estimated Net Worth of Pharmaceuticals (Europe) Lt... is at least $245 Million dollars as of 26 December 2018. Pharmaceuticals Lt owns over 40,198 units of CRISPR Therapeutics AG stock worth over $244,509,914 and over the last 6 years Pharmaceuticals sold CRSP stock worth over $0.
Pharmaceuticals has made over 2 trades of the CRISPR Therapeutics AG stock since 2018, according to the Form 4 filled with the SEC. Most recently Pharmaceuticals bought 40,198 units of CRSP stock worth $1,002,136 on 26 December 2018.
The largest trade Pharmaceuticals's ever made was buying 90,742 units of CRISPR Therapeutics AG stock on 21 December 2018 worth over $2,185,067. On average, Pharmaceuticals trades about 65,470 units every 3 days since 2018. As of 26 December 2018 Pharmaceuticals still owns at least 5,380,940 units of CRISPR Therapeutics AG stock.
You can see the complete history of Pharmaceuticals Lt stock trades at the bottom of the page.
Pharmaceuticals's mailing address filed with the SEC is 9TH, 2 Kingdom St, London W2 6BD, UK.
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani, and Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: